Reuters logo
BRIEF-Basilea Pharmaceutica: topline results of isavuconazole phase 3 study in candidemia
July 30, 2015 / 5:23 AM / in 2 years

BRIEF-Basilea Pharmaceutica: topline results of isavuconazole phase 3 study in candidemia

July 30 (Reuters) - Basilea Pharmaceutica AG :

* Reports topline results of isavuconazole phase 3 study in candidemia and other invasive Candida infections

* Results showed that study did not meet primary objective of demonstrating non-inferior efficacy of isavuconazole versus study comparator at end of i.v. therapy within pre-specified non-inferiority margin Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below